Ovid Therapeutics Inc.
OVID· Nasdaq
Released Nov 12, 2025, before the open
10-Q filed Nov 12, 2025, 43 days after period end · 0001636651-25-000012
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $132.00K | $173.00K | $109.00K | $11.10K |
| Net Income | -$12.16M | -$14.01M | -$11.25M | -$11.97M |
| EPS Diluted |
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
| — |
| -$0.20 |
| -$0.16 |
| -$0.17 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.